Top

Journal of Interventional Cardiac Electrophysiology

Published in:

01-08-2011

Rapid hemostasis at the femoral venous access site using a novel hemostatic pad containing kaolin after atrial fibrillation ablation

Authors: Akinori Sairaku, Yukiko Nakano, Noboru Oda, Yuko Makita, Kenta Kajihara, Takehito Tokuyama, Yasuki Kihara

Published in: Journal of Interventional Cardiac Electrophysiology | Issue 2/2011

Abstract

Background

Hemostasis at the femoral venous access site after atrial fibrillation (AF) ablation is often prolonged because of aggressive anticoagulation and the use of several large-sized sheaths. A newly developed hemostatic pad containing a natural mineral called kaolin causes blood to clot quickly. We evaluated the efficacy of this pad for hemostasis at the venous access site after AF ablation.

Methods

Patients who were scheduled to undergo AF ablation were randomized to be treated with manual compression with (n = 59) or without kaolin-impregnated pads (n = 59) as hemostatic approaches at the femoral venous access site following sheath removal. Hemostasis time, rebleeding frequency, massive hematoma, device-related complications, and deep venous thrombosis (DVT) were compared between the two groups.

Results

Hemostasis time in the patients treated with kaolin-impregnated pads was significantly shorter than in those treated without (6.1 ± 2.3 vs. 14.5 ± 4.0 min; p < 0.0001). Multiple linear regression analysis revealed that the use of kaolin-impregnated pads was the only independent variable reducing hemostasis time (β = −0.78; p < 0.0001). However, rebleeding rates of the two groups were similar (37% with vs. 46% without kaolin-impregnated pads; p = 0.35). Only one patient had a massive groin hematoma, and no patient had device-related complications or DVT.

Conclusions

Kaolin-impregnated hemostatic pads safely and effectively decreased hemostasis time for the femoral venous access site in patients undergoing AF ablation. However, whether its use allows earlier postprocedural ambulation is difficult to predict.

Kannel, W. B., Abbott, R. D., Savage, D. D., & McNamara, P. M. (1982). Epidemiologic features of chronic atrial fibrillation: the Framingham study. The New England Journal of Medicine, 306, 1018–1022.PubMedCrossRef

Haïssaguerre, M., Jaïs, P., Shah, D. C., Takahashi, A., Hocini, M., Quiniou, G., et al. (1998). Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. The New England Journal of Medicine, 339, 659–666.PubMedCrossRef

Pappone, C., Rosanio, S., Oreto, G., Tocchi, M., Gugliotta, F., Vicedomini, G., et al. (2000). Circumferential radiofrequency ablation of pulmonary vein ostia: A new anatomic approach for curing atrial fibrillation. Circulation, 102, 2619–2628.PubMed

Wyse, D. G., Waldo, A. L., DiMarco, J. P., Domanski, M. J., Rosenberg, Y., Schron, E. B., et al. (2002). A comparison of rate control and rhythm control in patients with atrial fibrillation. The New England Journal of Medicine, 347, 1825–1833.PubMedCrossRef

Ouyang, F., Bänsch, D., Ernst, S., Schaumann, A., Hachiya, H., Chen, M., et al. (2004). Complete isolation of left atrium surrounding the pulmonary veins: new insights from the double-Lasso technique in paroxysmal atrial fibrillation. Circulation, 110, 2090–2096.PubMedCrossRef

Cappato, R., Calkins, H., Chen, S. A., Davies, W., Iesaka, Y., Kalman, J., et al. (2005). Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation, 111, 1100–1105.PubMedCrossRef

Bertaglia, E., Zoppo, F., Tondo, C., Colella, A., Mantovan, R., Senatore, G., et al. (2007). Early complications of pulmonary vein catheter ablation for atrial fibrillation: a multicenter prospective registry on procedural safety. Heart Rhythm, 4, 1265–1271.PubMedCrossRef

Dagres, N., Hindricks, G., Kottkamp, H., Sommer, P., Gaspar, T., Bode, K., et al. (2009). Complications of atrial fibrillation ablation in a high-volume center in 1, 000 procedures: still cause for concern? Journal of Cardiovascular Electrophysiology, 20, 1014–1019.PubMedCrossRef

Ellis, E. R., Culler, S. D., Simon, A. W., & Reynolds, M. R. (2009). Trends in utilization and complications of catheter ablation for atrial fibrillation in Medicare beneficiaries. Heart Rhythm, 6, 1267–1273.PubMedCrossRef

10.

Kapadia, S. R., Raymond, R., Knopf, W., Jenkins, S., Chapekis, A., Ansel, G., et al. (2001). The 6Fr Angio-Seal arterial closure device: results from a multimember prospective registry. The American Journal of Cardiology, 87, 789–791.PubMedCrossRef

11.

Bhatt, D. L., Raymond, R. E., Feldman, T., Braden, G. A., Murphy, B., Strumpf, R., et al. (2002). Successful “pre-closure” of 7Fr and 8Fr femoral arteriotomies with a 6Fr suture-based device (the Multicenter Interventional Closer Registry). The American Journal of Cardiology, 89, 777–779.PubMedCrossRef

12.

Applegate, R. J., Grabarczyk, M. A., Little, W. C., Craven, T., Walkup, M., Kahl, F. R., et al. (2002). Vascular closure devices in patients treated with anticoagulation and IIb/IIIa receptor inhibitors during percutaneous revascularization. Journal of the American College of Cardiology, 40, 78–83.PubMedCrossRef

13.

Jaff, M. R., Hadley, G., Hermiller, J. B., Simonton, C., Hinohara, T., Cannon, L., et al. (2006). The safety and efficacy of the StarClose Vascular Closure System: the ultrasound substudy of the CLIP study. Catheterization and Cardiovascular Interventions, 68, 684–689.PubMedCrossRef

14.

Bangalore, S., Arora, N., & Resnic, F. S. (2009). Vascular closure device failure: frequency and implications: a propensity-matched analysis. Circulation. Cardiovascular Interventions, 2, 549–556.PubMedCrossRef

15.

Coto, H. A. (2002). Closure of the femoral vein puncture site after transcatheter procedures using Angio-Seal. Catheterization and Cardiovascular Interventions, 55, 16–19.PubMedCrossRef

16.

Mahadevan, V. S., Jimeno, S., Benson, L. N., McLaughlin, P. R., & Horlick, E. M. (2008). Pre-closure of femoral venous access sites used for large-sized sheath insertion with the Perclose device in adults undergoing cardiac intervention. Heart, 94, 571–572.PubMedCrossRef

17.

Kinnaird, T. D., Stabile, E., Mintz, G. S., Lee, C. W., Canos, D. A., Gevorkian, N., et al. (2003). Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. The American Journal of Cardiology, 92, 930–935.PubMedCrossRef

18.

Pristipino, C., Pelliccia, F., Granatelli, A., Pasceri, V., Roncella, A., Speciale, G., et al. (2007). Comparison of access-related bleeding complications in women versus men undergoing percutaneous coronary catheterization using the radial versus femoral artery. The American Journal of Cardiology, 99, 1216–1221.PubMedCrossRef

19.

Bertrand, O. F., Larose, E., Rodés-Cabau, J., Gleeton, O., Taillon, I., Roy, L., et al. (2009). Incidence, predictors, and clinical impact of bleeding after transradial coronary stenting and maximal antiplatelet therapy. American Heart Journal, 157, 164–169.PubMedCrossRef

20.

Cox, N., Resnic, F. S., Popma, J. J., Simon, D. I., Eisenhauer, A. C., & Rogers, C. (2004). Comparison of the risk of vascular complications associated with femoral and radial access coronary catheterization procedures in obese versus nonobese patients. The American Journal of Cardiology, 94, 1174–1177.PubMedCrossRef

21.

Byrne, J., Spence, M. S., Fretz, E., Mildenberger, R., Chase, A., Berry, B., et al. (2009). Body mass index, periprocedural bleeding, and outcome following percutaneous coronary intervention (from the British Columbia Cardiac Registry). The American Journal of Cardiology, 103, 507–511.PubMedCrossRef

22.

Chew, D. P., Bhatt, D. L., Lincoff, A. M., Moliterno, D. J., Brener, S. J., Wolski, K. E., et al. (2001). Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation, 103, 961–966.PubMed

23.

Hillegass, W. B., Brott, B. C., Chapman, G. D., Phillips, H. R., Stack, R. S., Tcheng, J. E., et al. (2002). Relationship between activated clotting time during percutaneous intervention and subsequent bleeding complications. American Heart Journal, 144, 501–507.PubMedCrossRef

24.

Brener, S. J., Moliterno, D. J., Lincoff, A. M., Steinhubl, S. R., Wolski, K. E., & Topol, E. J. (2004). Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention. Circulation, 110, 994–998.PubMedCrossRef

25.

Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., & Roth, D. (1999). A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Annals of Internal Medicine, 130, 461–470.PubMed

26.

Margolis, J. (1958). The kaolin clotting time; a rapid one-stage method for diagnosis of coagulation defects. Journal of Clinical Pathology, 11, 406–409.PubMedCrossRef

27.

Sugo, T., Kato, H., Iwanaga, S., Takada, K., & Sakakibara, S. (1985). Kinetic studies on surface-mediated activation of bovine factor XII and prekallikrein. Effects of kaolin and high-Mr kininogen on the activation reactions. European Journal of Biochemistry, 146, 43–50.PubMedCrossRef

28.

Politi, L., Aprile, A., Paganelli, C., Amato, A., Zoccai, G.B., Sgura, F., et al. (2010). Randomized clinical trial on short-time compression with kaolin-filled pad: a new strategy to avoid early bleeding and subacute radial artery occlusion after percutaneous coronary intervention. Journal of Interventional Cardiology, Aug 29. [Epub ahead of print].

29.

Sena, M. J., Larson, S., Piovesan, N., & Vercruysse, G. (2010). Surgical application of kaolin-impregnated gauze (Combat Gauze) in severe hemorrhagic gastritis. The American Surgeon, 76, 774–775.PubMed

30.

Nguyen, N., Hasan, S., Caufield, L., Ling, F. S., & Narins, C. R. (2007). Randomized controlled trial of topical hemostasis pad use for achieving vascular hemostasis following percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 69, 801–807.PubMedCrossRef

31.

Balzer, J. O., Schwarz, W., Thalhammer, A., Eichler, K., Schmitz-Rixen, T., & Vogl, T. J. (2007). Postinterventional percutaneous closure of femoral artery access sites using the Clo-Sur PAD device: initial findings. European Radiology, 17, 693–700.PubMedCrossRef

32.

Mlekusch, W., Minar, E., Dick, P., Sabeti, S., Bartok, A., Haumer, M., et al. (2008). Access site management after peripheral percutaneous transluminal procedures: Neptune pad compared with conventional manual compression. Radiology, 249, 1058–1063.PubMedCrossRef

33.

Palareti, G., Leali, N., Coccheri, S., Poggi, M., Manotti, C., D’Angelo, A., et al. (1996). Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet, 348, 423–428.PubMedCrossRef

34.

Patel, A. A., Clyne, C. A., Henyan, N. N., White, C. M., Zembrowski, B. F., Migeed, M., et al. (2007). The use of protamine after radiofrequency catheter ablation: a pilot study. Journal of Interventional Cardiac Electrophysiology, 18, 155–158.PubMedCrossRef

35.

Gianakos, S., Keeling, A. W., Haines, D., & Haugh, K. (2004). Time in bed after electrophysiological procedures (TIBS IV): a pilot study. American Journal of Critical Care, 13(56–58), 87.

36.

Strandness, D. E., & Summer, D. S. (1975). Hemodynamics for Surgeons (pp. 120–157). New York: Grune & Stratton Inc.

37.

Wazni, O. M., Beheiry, S., Fahmy, T., Barrett, C., Hao, S., Patel, D., et al. (2007). Atrial fibrillation ablation in patients with therapeutic international normalized ratio: comparison of strategies of anticoagulation management in the periprocedural period. Circulation, 116, 2531–2534.PubMedCrossRef

38.

Hussein, A. A., Martin, D. O., Saliba, W., Patel, D., Karim, S., Batal, O., et al. (2009). Radiofrequency ablation of atrial fibrillation under therapeutic international normalized ratio: a safe and efficacious periprocedural anticoagulation strategy. Heart Rhythm, 6, 1425–1429.PubMedCrossRef

39.

Schmidt, M., Segerson, N. M., Marschang, H., Akoum, N., Rittger, H., Clifford, S. M., et al. (2009). Atrial fibrillation ablation in patients with therapeutic international normalized ratios. Pacing and Clinical Electrophysiology, 32, 995–999.PubMedCrossRef

40.

Calkins, H., Brugada, J., Packer, D. L., Cappato, R., Chen, S. A., Crijns, H. J., et al. (2007). HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. Heart Rhythm, 4, 816–861.PubMedCrossRef

41.

Meyerovitz, M. F. (1990). How to maximize the safety of coronary and pulmonary angiography in patients receiving thrombolytic therapy. Chest, 97, 132S–135S.PubMed

Title: Rapid hemostasis at the femoral venous access site using a novel hemostatic pad containing kaolin after atrial fibrillation ablation
Authors: Akinori Sairaku
Yukiko Nakano
Noboru Oda
Yuko Makita
Kenta Kajihara
Takehito Tokuyama
Yasuki Kihara
Publication date: 01-08-2011
Publisher: Springer US
Published in: Journal of Interventional Cardiac Electrophysiology / Issue 2/2011
Print ISSN: 1383-875X
Electronic ISSN: 1572-8595
DOI: https://doi.org/10.1007/s10840-011-9552-6

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Rapid hemostasis at the femoral venous access site using a novel hemostatic pad containing kaolin after atrial fibrillation ablation

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2011

Risk factors associated with early- versus late-onset implantable cardioverter-defibrillator infections

Electroanatomic localization of a slowly conducting atrioventricular (Mahaim) accessory pathway

“Near-zero” fluoroscopic exposure in supraventricular arrhythmia ablation using the EnSite NavX™ mapping system: personal experience and review of the literature

High prevalence of right ventricular dysfunction in ICD patients with shocks: a potential new predictor in risk stratification

Unmappable ventricular tachycardia after an old myocardial infarction. Long-term results of substrate modification in patients with an implantable cardioverter defibrillator

Prediction of sudden cardiac death: next steps in pursuit of effective methodology

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page